Profile of:

Gareth Jones

Professor in Epidemiology - University of Aberdeen, UK. Non-clinical epidemiologist with research interests in aetiology, outcome, and management of axial spondyloarthritis / psoriatic arthritis / pain / fibromyalgia.

Full name: Gareth Jones

Current country: United Kingdom

Membership level: Full

Type of membership: Member

Number of publications: 25

Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis real-world patients treated with secukinumab for 24 months. (2024)

The risk of inflammatory bowel disease in patients with axial spondyloarthritis treated with biologic agents: BSRBR-AS and meta-analysis (2023)

One-third of European axial spondyloarthritis patients reach pain “remission” with routine care TNF-inhibitor treatment (2023)

The role of metrology in axSpA: does it provide unique information in assessing patients and predicting outcome? Results from the BSRBR-AS registry. (2022)

Enabling work participation for people with musculoskeletal conditions: lessons from work changes imposed by COVID-19: a mixed-method study. (2022)

Lessons from experiences of accessing healthcare during the pandemic for remobilising rheumatology services: a national mixed methods study. (2022)

Driving difficulties in patients with axial spondyloarthritis: results from the Scotland Registry for Ankylosing Spondylitis. (2022)

European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. (2022)

Generating EQ‑5D‑5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data (2022)

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA Collaboration (2022)

Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS. (2021)

Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis. (2021)

The changing states of fibromyalgia in patients with axial spondyloarthritis: results from the British Society of Rheumatology Biologics Register for Ankylosing Spondylitis. (2021)

Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS. (2021)

The effect of COVID19 public health restrictions on the health of people with musculoskeletal conditions and symptoms: the CONTAIN study. (2021)

Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis. (2021)

Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry. (2021)

Determining factors related to poor quality of life in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS). (2020)

Impact of smoking in response to tumor necrosis factor inhibitors in axial spondyloarthritis: methodologic considerations for longitudinal observational studies. (2020)

Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials? (2020)

Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis. (2020)

The prevalence of fibromyalgia in axial spondyloarthritis. (2020)

Impact of discordance between patient’s and evaluator’s global on TNFi retention and remission in 14868 spondyloarthritis patients. (2020)

Predicting response to anti-TNFα therapy amongst patients with axial spondyloarthritis (axSpA); results from BSRBR-AS. (2020)

Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: Results from the BSRBR-AS registry and meta-analysis. (2020)